Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Priority to UY27315ApriorityCriticalpatent/UY27315A1/en
Publication of UY27315A1publicationCriticalpatent/UY27315A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Derivados de pirimidina de la fórmula general I donde R1, R2, X, A y B tienen los significados mencionados en la memoria descriptiva, como inhibidores de quinasas dependientes de ciclina, su obtención y su uso como medicamento para el tratamiento de diferentes enfermedades.Pyrimidine derivatives of the general formula I where R1, R2, X, A and B have the meanings mentioned in the specification, such as cyclin-dependent kinase inhibitors, their obtaining and use as a medicine for the treatment of different diseases.
UY27315A2002-05-292002-05-29
CDK INHIBITING PYRIMIDINS, ITS PREPARATION AND USE AS A MEDICINAL PRODUCT.
UY27315A1
(en)
Compounds derived from pyrrole (2.3-d) pyrimidine. purin-6-yl or pyrazol (3,4-d) pyrimldine, p70 s6 kinase inhibitors; pharmaceutical composition; and use for the preparation of drugs useful in the treatment of colon adenocarcinomas and inhibition of angiogenesis.
2-ANILINOPIRIMIDINAS REPLACED AS INHIBITORS OF THE KINASE OF THE CELL CYCLE OR THE RECEIVER OF THE THYROSINE KINASE, ITS PREPARATION AND ITS USE AS MEDICATIONS
SUBSTITUTED DERIVATIVES OF THE N- (3-OXO-2,3-DIHIDRO-1H-ISOINDOL-4-IL) -1-NAFTAMIDE, PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS